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Temozolomide (TMZ) is an alkylating drug
most often used in the treatment of primary brain
malignancies. Herein, we report an unusual cu-
taneous adverse drug reaction (ADR) associated
with TMZ and characterized by temporally dis-
tinct dermal and subcutaneous hypersensitivity
reactions.REPORT OF A CASE
A woman in her 70s had right frontal anaplastic
astrocytoma (World Health Organization grade III).
The patient underwent a gross total tumor resec-
tion and a 6-week course of postoperative radia-
tion therapy (6000 cGy) with concurrent TMZ (75
mg/m2) by mouth daily. Four weeks after comple-
tion of radiation, she started adjuvant TMZ (150
mg/m2 by mouth), following the standard schedule
for high-grade gliomas (5 consecutive days per 28-
day cycle). During the second cycle, she had
persistent red tender subcutaneous nodules on
her bilateral thighs without associated systemic
symptoms (Fig 1). There was no history of any
recent infections or other new medications, and
there was no personal or family history of inflam-
matory bowel disease, sarcoidosis, lupus erythe-
matosus, or chronic lower extremity edema.
Histopathologic examination of 2 skin biopsies
sections found mixed septal and lobular pannicu-
litis with a mixed cell inflammatory infiltrate con-
taining eosinophils (Fig 2, A). Antinuclear antibody
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within normal limits. The skin nodules spontane-
ously resolved over a few months without TMZ
dose reduction or other specific intervention. TMZ
was discontinued after 6 cycles.
The patient remained in disease remission until 2
years later when a nodular enhancement consistent
with recurrence was noted on surveillance magnetic
resonance imaging. She was restarted on TMZ (150
mg/m2) by mouth daily for 5 consecutive days per
28-day cycle. Within 10 days of resuming TMZ, the
patient noted an itchy rash with persistent individual
lesions that did not come and go. On cutaneous
examination, discrete red plaques and nodules were
found on the bilateral upper extremities, thighs, and
back (Fig 3). Histopathologic examination of a skin
biopsy specimen found a perivascular and interstitial
lymphocytic infiltrate with abundant eosinophils,
early flame figures, and dermal edema, consistent
with a dermal hypersensitivity reaction (Fig 2, B).1
The patient denied recent arthropod bites, travel,
and new prescription or over-the-counter medica-
tions. A complete blood cell count was within
normal limits. Despite use of topical clobetasol,
0.05% ointment twice daily, and hydroxyzine, 25
mg by mouth 3 times daily, the rash persisted, and
she developed new persistent skin nodules. SheCancer Center, 16 E. 60th Street, New York, NY 10022. E-mail:
marchetm@mskcc.org.
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Fig 1. Clinical overview image of the legs shows subcu-
taneous red nodules on the bilateral lower extremities
(black arrows).
Fig 2. Representative photomicrographs of skin biopsies.
A, Septal and lobular panniculitis with a mixed cell
infiltrate containing numerous eosinophils. B, Dermal
mixed cell infiltrate with abundant eosinophils, early flame
figures, and edema. (A and B, Hematoxylin-eosin stain;
original magnifications: A, 320; B, 340.)
Fig 3. Clinical overview image shows red plaques and
nodules on the back.
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mg daily for 1 week, 40 mg daily for 1 week, 20 mg
daily for 1 week) with improvement but not resolu-
tion of her symptoms. Progression of disease was
then noted on magnetic resonance imaging, and the
patient discontinued TMZ therapy to start a clinical
trial. Within 2 to 3 weeks of discontinuing TMZ, allskin lesions resolved. After 7 months of follow-up,
the patient had not experienced any recurrence of
her rash.DISCUSSION
The reported dermatologic side effects of TMZ are
limited but include urticaria, desquamative and
maculopapular rash, alopecia, Stevens-Johnson syn-
drome/toxic epidermal necrolysis, and palmo-
plantar erythrodysesthesia.2 Among 300 Korean
patients with malignant glioma treated with TMZ,
16 (5.3%) had skin rash, most frequently Common
Terminology Criteria for Adverse Events grade 2 or
lower (n = 15, 94%).3,4 Of note, the authors found
that patients treated with TMZ and concomitant
radiotherapy were more likely to have skin rash
than patients treated with TMZ and no concomitant
radiotherapy (7.2% vs 2.5%, P = .02).4 Pothiawala
et al5 suggested that the apparently low rate of
cutaneous ADRs from TMZ can be explained in
part by concomitant use of corticosteroids, which are
frequently used in patients with high-grade gliomas
to reduce edema associated with radiation or tumor
growth.
Although we were unable to identify a published
report of an ADR associated with TMZ administra-
tion with similar clinicopathologic features, the
likelihood that TMZ was responsible is possible
(score of 3) for the first episode of rash and probable
(score of 7) for the second episode of rash, accord-
ing to the Naranjo ADR probability scale.6 The
findings in our case emphasize the important need
for clinicopathologic correlation in evaluating pa-
tients with nonspecific skin biopsies. Fung1 found
that follow-up in 74 of 110 patients with a skin
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reaction eventually revealed, most commonly, di-
agnoses of urticaria, drug reactions, and spongiotic
(eczematous) dermatitis. In addition, the role of
drugs in panniculitides is often not considered, as
the clinical and histologic features of drug-induced
panniculitides are often indistinguishable from
those caused by other etiologies.7 Clinicians should
remain cognizant that cutaneous ADRs remain great
masqueraders.
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